Study Shows Higher Dose Of Toviaz ® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder The safety and tolerability profile of ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) approved TOVIAZ TM (fesoterodine fumarate) extended release tablets for the treatment of overactive ...

Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz(fesoterodine fumarate) in patients with overactive bladder (OAB) met its primary endpoint.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients ...

Patients treated with Toviaz® (fesoterodine fumarate) 8 mg extended release tablets had greater and statistically significant reductions in urge urinary incontinence episodes at week 12 (P=0.017) ...

Study Shows Higher Dose Of Toviaz ® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.

Structurally related to the most prescribed OAB medication, Pfizer ´ s Detrol ® LA (tolterodine tartrate extended release capsules), TOVIAZ can help regulate the involuntary contractions of the ...